Clene to Present at Upcoming Investor Conferences

SALT LAKE CITY, May 16, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences:

• H.C. Wainwright Global Investment Conference, May 24-26, 2022Presentation Time: May 25, 2022, at 2 p.m. ET

• Benchmark Healthcare House Call Virtual 1x1 Conference, June 2, 2022
• JMP Securities Life Sciences Conference, June 15-16, 2022Presentation Time: June 15, 2022, at 2 p.m. ET

About CleneClene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

Media Contact Erica Fiorini, Ph.D., or David Schull Russo Partners, LLC [email protected] [email protected] +1-212-845-4253

Investor Contact John Woolford Managing Director, Westwicke [email protected] +1-443-213-0506

Source: Clene Inc.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Automatic Trap Company Gives Homeowners a Poison-Free Tool for Every Pest As Summer Rodent Season Peaks Across California
• DAVID WEEKLEY HOMES ANNOUNCES 2026 NATIONAL PREFERRED PARTNERS